Natalie O Karpinich1, Kathleen M Caron2. 1. From the Department of Cell Biology and Physiology (N.O.K., K.M.C.) and Department of Genetics (K.M.C.), University of North Carolina at Chapel Hill. 2. From the Department of Cell Biology and Physiology (N.O.K., K.M.C.) and Department of Genetics (K.M.C.), University of North Carolina at Chapel Hill. kathleen_caron@med.unc.edu.
Abstract
OBJECTIVE: The lymphatic vasculature is a well-established conduit for metastasis, but the mechanisms by which tumor cells interact with lymphatic endothelial cells (LECs) to facilitate escape remain poorly understood. Elevated levels of the lymphangiogenic peptide adrenomedullin are found in many tumors, and we previously characterized that its expression is necessary for lymphatic vessel growth within both tumors and sentinel lymph nodes and for distant metastasis. APPROACH AND RESULTS: This study used a tumor cell-LEC coculture system to identify a series of adrenomedullin-induced events that facilitated transendothelial migration of the tumor cells through a lymphatic monolayer. High levels of adrenomedullin expression enhanced adhesion of tumor cells to LECs, and further analysis revealed that adrenomedullin promoted gap junction coupling between LECs as evidenced by spread of Lucifer yellow dye. Adrenomedullin also enhanced heterocellular gap junction coupling as demonstrated by Calcein dye transfer from tumor cells into LECs. This connexin-mediated gap junction intercellular communication was necessary for tumor cells to undergo transendothelial migration because pharmacological blockade of this heterocellular communication prevented the ability of tumor cells to transmigrate through the lymphatic monolayer. In addition, treatment of LECs with adrenomedullin caused nuclear translocation of β-catenin, a component of endothelial cell junctions, causing an increase in transcription of the downstream target gene C-MYC. Importantly, blockade of gap junction intercellular communication prevented β-catenin nuclear translocation. CONCLUSIONS: Our findings indicate that maintenance of cell-cell communication is necessary to facilitate a cascade of events that lead to tumor cell migration through the lymphatic endothelium.
OBJECTIVE: The lymphatic vasculature is a well-established conduit for metastasis, but the mechanisms by which tumor cells interact with lymphatic endothelial cells (LECs) to facilitate escape remain poorly understood. Elevated levels of the lymphangiogenic peptide adrenomedullin are found in many tumors, and we previously characterized that its expression is necessary for lymphatic vessel growth within both tumors and sentinel lymph nodes and for distant metastasis. APPROACH AND RESULTS: This study used a tumor cell-LEC coculture system to identify a series of adrenomedullin-induced events that facilitated transendothelial migration of the tumor cells through a lymphatic monolayer. High levels of adrenomedullin expression enhanced adhesion of tumor cells to LECs, and further analysis revealed that adrenomedullin promoted gap junction coupling between LECs as evidenced by spread of Lucifer yellow dye. Adrenomedullin also enhanced heterocellular gap junction coupling as demonstrated by Calcein dye transfer from tumor cells into LECs. This connexin-mediated gap junction intercellular communication was necessary for tumor cells to undergo transendothelial migration because pharmacological blockade of this heterocellular communication prevented the ability of tumor cells to transmigrate through the lymphatic monolayer. In addition, treatment of LECs with adrenomedullin caused nuclear translocation of β-catenin, a component of endothelial cell junctions, causing an increase in transcription of the downstream target gene C-MYC. Importantly, blockade of gap junction intercellular communication prevented β-catenin nuclear translocation. CONCLUSIONS: Our findings indicate that maintenance of cell-cell communication is necessary to facilitate a cascade of events that lead to tumor cell migration through the lymphatic endothelium.
Authors: Solveig Sirnes; Guro E Lind; Jarle Bruun; Tone A Fykerud; Marc Mesnil; Ragnhild A Lothe; Edgar Rivedal; Matthias Kolberg; Edward Leithe Journal: Int J Cancer Date: 2014-05-05 Impact factor: 7.396
Authors: Barbara Garmy-Susini; Christie J Avraamides; Michael C Schmid; Philippe Foubert; Lesley G Ellies; Leo Barnes; Chloe Feral; Thalia Papayannopoulou; Andrew Lowy; Sarah L Blair; David Cheresh; Mark Ginsberg; Judith A Varner Journal: Cancer Res Date: 2010-04-13 Impact factor: 12.701
Authors: J D Shields; M S Emmett; D B A Dunn; K D Joory; L M Sage; H Rigby; P S Mortimer; A Orlando; J R Levick; D O Bates Journal: Oncogene Date: 2006-11-27 Impact factor: 9.867
Authors: S J Mandriota; L Jussila; M Jeltsch; A Compagni; D Baetens; R Prevo; S Banerji; J Huarte; R Montesano; D G Jackson; L Orci; K Alitalo; G Christofori; M S Pepper Journal: EMBO J Date: 2001-02-15 Impact factor: 11.598
Authors: Natalie O Karpinich; Daniel O Kechele; Scott T Espenschied; Helen H Willcockson; Yuri Fedoriw; Kathleen M Caron Journal: FASEB J Date: 2012-10-25 Impact factor: 5.191
Authors: Claire E Trincot; Wenjing Xu; Hua Zhang; Molly R Kulikauskas; Thomas G Caranasos; Brian C Jensen; Amélie Sabine; Tatiana V Petrova; Kathleen M Caron Journal: Circ Res Date: 2019-01-04 Impact factor: 17.367
Authors: Brooke C Matson; Stephanie L Pierce; Scott T Espenschied; Eric Holle; Imani H Sweatt; Eric S Davis; Robert Tarran; Steven L Young; Trudy A Kohout; Marcel van Duin; Kathleen M Caron Journal: Biol Reprod Date: 2017-09-01 Impact factor: 4.285
Authors: Trond Aasen; Edward Leithe; Sheila V Graham; Petra Kameritsch; María D Mayán; Marc Mesnil; Kristin Pogoda; Arantxa Tabernero Journal: Oncogene Date: 2019-02-27 Impact factor: 9.867